<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 2)
TUTOGEN MEDICAL INC.
_________________________________________________________________________
(Name of Issuer)
COMMON STOCK
_______________________________________________________________________
(Title of Class of Securities)
09058X109
__________________________
(CUSIP Number)
<PAGE>
<PAGE> 2
13G
CUSIP No. 09058X109
_____________________________________________________________________________
1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO.
Renaissance Capital Partners II, Ltd. 75-2407159
_____________________________________________________________________________
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a)
(b)
_____________________________________________________________________________
3. SEC USE ONLY
_____________________________________________________________________________
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Texas
_____________________________________________________________________________
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
_____________________________________________________________________________
5. SOLE VOTING POWER
7,232,668 shares
_____________________________________________________________________________
6. SHARED VOTING POWER
None
_____________________________________________________________________________
7. SOLE DISPOSITIVE POWER
7,232,668 shares
_____________________________________________________________________________
8. SHARED DISPOSITIVE POWER
None
_____________________________________________________________________________
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,232,668 shares
_____________________________________________________________________________
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
Not applicable
_____________________________________________________________________________
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
60.77%
_____________________________________________________________________________
12. TYPE OF REPORTING PERSON
PN, IV
_____________________________________________________________________________
<PAGE>
<PAGE> 3
ITEM 1.
a, b. Tutogen Medical Inc. ( Company )
1719 Route 10, Suite 314
Parsippany, NJ 07054
ITEM 2.
(a) Name of Person Filing
Renaissance Capital Partners II, Ltd. ( Filer )
(b) Address of principal Business Office or, if none, Residence
8080 N. Central Expwy., Suite 210 LB-59
Dallas, TX 75206-1857
(c) Citizenship
Texas
(d) Title of Class of Securities
Common Stock
(e) CUSIP Number
759922206
ITEM 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-
2(b), check whether the person filing is a:
(a) ______ Broker or Dealer registered under Section 15 of the Act
(b) ______ Bank as defined in section 3(a)(6) of the Act
(c) ______ Insurance Company as defined in section 3(a)(19) of the
Act
(d) __X___ Investment Company registered under section 8 of the
Investment Company Act
(e) ______ Investment Adviser registered under section 203 of the
Investment Advisers Act of 1940
(f) ______ Employee Benefit Plan, Pension Fund which is subject to
the provisions of the Employee Retirement Income Security
Act of 1974 or Endowment Fund; see 240.13d-1(b)(1)(ii)(F)
(g) ______ Parent Holding Company, in accordance with 240.13d-
1(b)(ii)(G)(Note: See Item 7)
(h) ______ Group, in accordance with 240.13d-1(b)(1)(ii)(H)
Item 4. Ownership.
(a) Amount Beneficially Owned:
At December 31, 1998, the Filer s reportable position in the Company
was 695,110 shares of the Company's common stock, $2,074,081.06 in a
Convertible Debenture, which is convertible into common stock at
$0.4699688 per share, $ 500,000 in a Convertible Debenture which is
convertible into common stock at $1.35 per share, a warrant to
purchase 547,560 common shares at $2.50 per share, a warrant to
purchase 806,397 common shares at $2.60 per share, a warrant to
purchase 400,000 common shares at $1.25 per share. All of the
debentures and warrants are convertible or exercisable within 60 days.
<PAGE>
<PAGE> 4
(b) Percent of Class
60.77%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
7,232,668
(ii) shared power to vote or to direct the vote:
None
(iii) sole power to dispose or to direct the disposition of:
7,232,668
(iv) shared power to dispose or to direct the disposition of:
None
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more
than five percent of the class of securities, check the following:
Item 6. Ownership of More than Five Percent on Behalf of Another
Person.
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding
Company.
Not applicable.
Item 8. Identification and Classification of Members of the Group.
Not applicable.
Item 9. Notice of Dissolution of Group.
Not applicable.
<PAGE>
<PAGE> 5
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were acquired in the ordinary course of
business and were not acquired for the purpose of and do not have the effect
of changing or influencing the control of the issuer of such securities and
were not acquired in connection with or as a participant in any transaction
having such purposes or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
Date: January 26, 1999
________________/S/___________________________
Signature
Thomas W. Pauken, Liquidation Trustee
Renaissance Capital Partners II, Ltd.
___________________________________________
Name and Title
<PAGE>
